Cancer/Tumor Profiling Market – A $26.31 Billion Industry Opportunity, Solution to Personalized Cancer Care

The Global Cancer/Tumor Profiling Market is projected to increase at a CAGR value of 11.87% to surpass 26.31 Billion during the Forecast Period of 2022-2030; Rising number of Cancer Cases and increased demand for personalized medicine to boost the industry growth.


New York, USA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The market size of Cancer/Tumor Profiling in 2021 was USD 9.59 billion and will be worth USD 26.31 billion by 2030, growing at an 11.87% CAGR. Based on the technology used, Cancer/Tumor profiling is a test that aids in genome sequencing at a quick pace with higher efficacy. As cancer is a known inheritable condition, this test not only focuses on sequencing but also aids in estimating the extent to which cancer can spread.


Make a Direct Purchase of the latest Cancer/Tumor Profiling Market Report published in the month of Dec-2021. Click the below link to initiate the purchase: 

https://www.strategicmarketresearch.com/buy-now/cancer-tumor-profiling-market



The Cancer/Tumor Profiling Market Insights: 

  • The immunoassays segment ruled the entire market with a 6.89% CAGR on the basis of technology.
  • The breast cancer segment held a significant position with the largest market share in 2020 on the basis of cancer type.
  • On the basis of biomarker type, the genomic biomarker segment ruled the overall market with a significant 6.713% CAGR.
  • The largest market was contributed by research applications with a rapid 7.93% CAGR on the basis of application.
  • North America significantly ruled the entire market, with a share of 48.8% in 2020.

Factors influencing the Cancer/Tumor Profiling Market growth

Factors such as the increasing number of cancer cases and increased demand for personalized medicine are expanding the overall growth rate of the market. 

  • According to WHO reports, cancer cases rose to 19.3 million in 2020, with 10 million deaths globally. Breast and lung cancer recorded 23.1% of all cancer cases among the new cases. Due to the rapidly increasing number of cancer cases, major players have significantly increased their investments in the development of novel technologies for cancer profiling, which is anticipated to support market revenue growth.

  • The global Cancer/Tumor profiling market will grow due to the increasing demand for personalized medicine. The classification, detection, and treatment of most diseases are being transformed by personalized medicine, which has become a standard of clinical practice.

Cancer/Tumor Profiling Market Segmentation Analysis

The market segmentation of Cancer/Tumor profiling is based on technology, cancer type, biomarker type, application, and Region. 

By Technology

  • In-Situ Hybridization
  • PCR (Polymerized Chain Reaction)
  • Immunoassays
  • Microarrays
  • NGS (Next-generation sequencing)
  • Others

By Cancer Type

  • Prostate Cancer
  • Melanoma Cancer
  • Breast Cancer
  • Colon Cancer
  • Lung Cancer

By Biomarker Type

  • Genomic Biomarkers
  • Protein Biomarkers
  • Others

By Applications

  • Prognostics
  • Clinical Applications
  • Screening
  • Diagnostics
  • Research Applications
  • Others

For Region

North America

  • Canada
  • USA
  • Mexico
  • Rest of North America

Asia-Pacific 

  • Australia
  • Japan
  • India
  • Malaysia
  • Thailand
  • Philippines
  • South Korea
  • Singapore
  • Indonesia
  • China
  • Rest of APAC

Europe 

  • Italy
  • Spain
  • Belgium
  • Netherlands
  • Finland
  • Switzerland
  • Turkey
  • Russia
  • U.K.
  • Germany
  • France
  • The rest of Europe 

LAMEA

  • Saudi Arabia
  • Brazil
  • Uruguay
  • Argentina
  • South Africa
  • Rest of LAMEA


To get a first-hand overview of the report, Request a Sample at
https://www.strategicmarketresearch.com/request-sample/cancer-tumor-profiling-market


The immunoassays segment ruled the entire market with a 6.89% CAGR on the basis of technology. The increasing use of these assays for cancer profiling on a global scale, coupled with some key insights into how to reduce the severity of illnesses and shorten hospital stays, are immensely promoting the growth of this market.

The largest market was contributed by research applications with a rapid 7.93% CAGR on the basis of application. The market growth is stimulated by increased funding for the construction of cancer research and testing facilities around the world, an increase in the use of personalized medicine, and a strong emphasis on the invention of biomarkers for drug development.

North America significantly ruled the entire market, with a share of 48.8% in 2020. The enormous funding required for conducting cancer tumour profiling research and development projects and the ongoing development of cutting-edge cancer screening technologies are driving the market expansion in this area.


Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.
https://www.strategicmarketresearch.com/pre-order-enquiry/cancer-tumor-profiling-market


Cancer Profiling Market Report Coverage

Report AttributeDetails
Forecast Period2021 - 2030
The market size value in 2021USD 9.59 billion
The revenue forecast in 2030USD 26.31 billion
Growth rateCAGR of 11.87 %
The base year for estimation2021
Historical data2017 – 2020
UnitUSD Billion, CAGR (2021 - 2030)
SegmentationBased on Technology, Based on Cancer Type, Based on Biomarker Type, Based on Applications, and By region.
Based on TechnologyImmunoassays, PCR (Polymerized Chain Reaction), NGS (Next-generation sequencing), Microarrays, In-Situ Hybridization, Others
Based on Cancer TypeLung Cancer, Breast Cancer, Colon Cancer, Melanoma Cancer, Prostate Cancer
Based on Biomarker TypeProtein Biomarkers, Genomic Biomarkers, Others
Based on ApplicationsResearch Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Others
By RegionNorth America, Europe, Asia-Pacific, and LAMEA
Country ScopeUS, Mexico, Canada, Germany, UK, France, China, Japan, India, etc.
Company Usability ProfilesIllumina Inc., NeoGenomics Laboratories Inc., QIAGEN N.V., Genomic Health Inc., Caris Life Sciences, HTG Molecular Diagnostics Inc.,  Helomics Corporation, Sysmex Corporation, Elevation Oncology, Ribomed Biotechnologies Inc., NanoString Technologies Inc., Guardant Health Inc., Roche Diagnostics, GenScript Biotech Corporation, Tempus Labs, Boreal Genomics Inc, Perthera, Agendia, Omniseq, Histogene X
Pricing and purchase optionsCustomized buying options are available to meet your exact research needs.


Key players in Cancer/Tumor Profiling Market:

  • QIAGEN N.V. 
  • Genomic Health Inc. 
  • NeoGenomics Laboratories Inc. 
  • Caris Life Sciences
  • Ribomed Biotechnologies Inc.
  • NanoString Technologies Inc. 
  • Tempus Labs
  • Illumina Inc. 
  • Helomics Corporation 
  • Sysmex Corporation
  • Elevation Oncology
  • Perthera
  • Agendia
  • Guardant Health Inc.
  • Roche Diagnostics
  • GenScript Biotech Corporation
  • Omniseq
  • Histogene X
  • Boreal Genomics Inc

To read the summary of the report, visit the website at
https://www.strategicmarketresearch.com/market-report/cancer-tumor-profiling-market


Recent Developments

  • To improve the usability of the results of comprehensive genomic profiling (CGP), Foundation Medicine, Inc., a leader in molecular profiling for cancer, announced the release of FoundationReport+, a new interactive digital report.

  • Oncology startup 4baseCare announced collaboration with AstraZeneca India to improve cancer treatment in India. The organizations will work together to provide targeted therapy options for patients with advanced cancer using reasonably priced genomic solutions.
  • The combination of AstraZeneca's IMFINZI and IMJUDO plus platinum based chemotherapy has been granted approval in the United States for treating adult patients with Stage IV (metastatic) non small cell lung cancer (NSCLC).

Related Reports

Global Hormone Replacement Therapy Market Report
The Hormone Replacement Therapy Market report gives a detailed analysis of its growth factors, challenges, restraints, opportunities, etc. The Hormone Replacement Therapy Market in 2021 was worth USD 24.97 Billion and will be USD 49.25 Billion in 2030, growing at a 7.83% CAGR. The increasing incidence of menopausal illness and rising awareness about post menopausal difficulties in women are expediting its growth rate. Significant players in this market are Merck Kgaa, Bayer Ag., Abbott Laboratories, Novartis International Ag, Pfizer Inc., etc.

Global Orthopedic Biomaterials Market Report
SMR's Orthopedic Biomaterials Market Report analyses its challenges, growth factors, restraints, and opportunities. The Orthopedic Biomaterials Market in 2021 was worth USD 16.06 Billion, and it will be USD 39.11 Billion with a 10.36% CAGR. The rising geriatric population is the key factor stimulating the market expansion. Significant participants in this market are DePuy Synthes, Collagen Matrix Inc., Medtronic Plc., Globus Medical, Invibil Ltd., etc.

Global Surgical Microscope Market Report
The Surgical Microscope Market Report by SMR gives an overview of augmenting factors, challenges, restraints, etc. The Surgical Microscope Market in 2021 was USD 1077.087 billion and will be USD 2928.17 billion by 2030, representing an 11.75% CAGR. Rapid technological developments and a rise in the rate of surgeries globally are boosting market expansion. Prominent Companies in this market are Accu-Scope Inc, Alcon Inc., Seiler Instruments Inc., Leica Microsystems, Olympus Corp., etc.

Global Multiplex Assays Market Report
The Multiplex Assays Market Report by SMR outlines its opportunities, challenges, restraints, etc. The Multiplex Assays Market worth in 2021 was USD 3.36 Billion and will reach USD 6.47 Billion by 2030 with a 7.53% CAGR. The increasing rate of non-communicable diseases and infectious diseases and the rise in the use of multiplex assays are the factors influencing market expansion. Major participants operating in this industry include Abcam plc, Meso Scale Diagnostics, Thermo Fisher Scientific Inc, Qiagen N.V., Olink, Seegene, etc.

Global Single Cell Analysis Market Report
SMR's Single Cell Analysis Market Report provides insights into its growth factors, challenges, opportunities, restraints, etc. The Single Cell Analysis Market in 2021 was worth USD 2.79 Billion, and by 2030 it will be USD 10.31 Billion, growing at a 15.6% CAGR. Factors like technological developments, growing focus on personalized medicine, and increased R&D in the single-cell analysis are accelerating its growth rate. Prominent businesses in this market are Becton, BGI, Qiagen, Merck Millipore, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., etc.

About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.

Contact Us:
Strategic Market Research LLP.
Sunil Kumar 
India: +91-8260836500
Email: info@strategicmarketresearch.com
Web: https://www.strategicmarketresearch.com
Blog: https://www.strategicmarketresearch.com/blog
Blog: https://www.strategicmarketresearch.com/blogs/metaverse-statistics
Press Release: https://www.strategicmarketresearch.com/press-releases

Connect Us:
LinkedIn: https://www.linkedin.com/company/strategic-market-research/
Twitter: https://twitter.com/smrstrategic
Facebook: https://www.facebook.com/StrategicMarketResearch
Instagram: https://www.instagram.com/strategicmarketresearchsmr/